Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCDHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LUCD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $72.57M
- EPS (TTM)
- -$0.36
- Dividend yield
- None
- 52-week range
- 0.303 – 1.63
- Day range
- 0.3545 – 0.3946
- Volume / Avg
- 2.26M / 5.15M
- Beta
- —
- Shares outstanding
- 194.71M
52-week range
LUCD stock today
On Nov 20, LUCD ended the session at $0.3727, shedding $0.0136 (3.52%), versus the S&P 500's 3.70% decline. Trading was light, with 2.26M shares changing hands, about 44% of the average daily volume. At this level, LUCD sits near the bottom of its 52-week range of $0.303 to $1.63: 77.1% below the high, set on Jan 21, 2026 and 23.0% above the low.
LUCD is down 65.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 64.7%. Lucid Diagnostics has posted a net loss over the last twelve months (EPS of -$0.36), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lucid Diagnostics
Company profileLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Dr. Lishan Aklog M.D.
- Headquarters
- New York, NY
- Employees
- 82
- IPO year
- 2021
- Website
- luciddx.com
Financial highlights
Full financialsIn fiscal 2025, Lucid Diagnostics generated $4.7 million in revenue, up 8.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Lucid Diagnostics reported a net loss of $58.0 million, compared with a loss of $45.5 million a year earlier. Gross margin was -41.7% (up from -63.3%) and operating margin -1054.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.71M | $4.35M | $2.43M | $377.00K | $500.00K |
| Growth | +8.28% | +79.00% | +544.03% | -24.60% | — |
| Net income | $-58.01M | $-45.53M | $-52.67M | $-56.17M | $-28.08M |
| EPS (diluted) | — | $-1.05 | $-1.26 | $-1.55 | $-1.51 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$4.00+973.25%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.07 vs $-0.07
- Surprise
- 0.00%
LUCD news
All LUCD news- Lucid Diagnostics Reports Third Quarter 2026 Financial ResultsNasdaq
- Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue EstimatesNasdaqMTD, LUCD
- Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive YearPR NewswireLUCD, PAVM
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumPR NewswireLUCD, PAVM
- Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® StudyPR Newswire
- Biotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMABNasdaqBOLT, GMAB, LUCD, LYCA
- Lucid Diagnostics Inc. Closes $15.0 million Series C Preferred Stock OfferingNasdaq
- 3 Key Reasons to Buy This Huge Turnaround Story That's Gaining TractionNasdaqSTLA, F, GM, LUCD
Lucid Diagnostics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QTEXQTREX Quantum Ltd. | 1.00 | -10.71% | $70.63M | vs LUCD |
| SKINSkinHealth Systems Inc. Class A | 11.77 | -3.13% | $76.68M | vs LUCD |
| NYXHNyxoah SA | 0.805 | -7.01% | $81.98M | vs LUCD |
| LNSRLENSAR Inc. | 4.46 | -3.88% | $54.83M | vs LUCD |
| MBOTMicrobot Medical Inc. | 0.68 | -8.52% | $45.67M | vs LUCD |
| APYXApyx Medical Corporation | 2.40 | +0.42% | $101.10M | vs LUCD |
| DXRDaxor Corporation | 7.45 | -7.33% | $43.49M | vs LUCD |
| SRTSSensus Healthcare Inc. | 2.26 | -4.24% | $37.20M | vs LUCD |
Indexes, lists and sector
Lucid Diagnostics stock FAQ
What is Lucid Diagnostics's stock price today?
LUCD last traded at $0.3727 as of Nov 20, 4:00 PM EST, down 3.52% on the day. Prices are delayed at least 15 minutes.
Who is Lucid Diagnostics's CEO?
Dr. Lishan Aklog M.D. is the chief executive officer of Lucid Diagnostics Inc., which has about 82 employees.
What is the LUCD 52-week high?
The 52-week high for LUCD is $1.63 and the 52-week low is $0.303. The stock is currently 77.1% below its high.